Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects

Trial Profile

A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2019

At a glance

  • Drugs Nomacopan (Primary)
  • Indications Bullous pemphigoid
  • Focus Adverse reactions
  • Sponsors Akari Therapeutics
  • Most Recent Events

    • 17 Aug 2018 According to an Akari Therapeutics media release, data from this study is expected in Q1 2019.
    • 01 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top